SiriusPoint (NYSE:SPNT) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.30) by 103.33 percent. This is a 79.41 percent decrease over losses of $(0.34) per share from the same period last year.
OncoSec Announces $1.33M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to
